000			02051na a2200277 4500
003			PC2514
005			20210625062757.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aSerna Torroba, Javier de la _91469 _eHematología y Hemoterapia
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
100			_aRapado Martínez, Inmaculada _91468 _eInstituto de Investigación
100			_aRivero Ruiz, Ana _91489 _eInstituto de Investigación
245	0	0	_aRelationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma _h[artículo]
260			_bLeukemia Research, _c2011.
300			_a35(4):431-437.
500			_aFormato Vancouver: Rivero A, Rapado I, Tomás JF, Montalbán C, De Oña R, Paz Carreira J, et al. Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leuk Res. 2011;35(4):431-7.
501			_aPMID: 21030078
504			_aContiene 38 referencias.
520			_aDCK catalyzes the intracellular phosphorylation of fludarabine. The promoter and coding region of the DCK gene were analyzed in 74 follicular lymphoma (FL) patients receiving a therapeutic regimen that included fludarabine. DCK mRNA expression was quantified in a cohort of healthy donors. Four previously described genotypic variants, -360C>G, -201C>T (rs2306744), C28624T (rs11544786) and c.91+37G>C (rs9997790), as well as the new variant, -12C>G, were identified. Variant C28624T showed a lower risk of lymphopenia (P=0.04), but a higher risk of neutropenia (P=0.04). Statistical significance was found in bivariate logistic regression between lymphopenia and infectious episodes in the induction period (odds ratio 3.85, P=0.04).
710			_9297 _aServicio de Hematología y Hemoterapia
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc2514.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c2514 _d2514